Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae

David C. Richardson, Darrin Bast, Allison McGeer, Donald E. Low
David C. Richardson
Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darrin Bast
Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison McGeer
Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald E. Low
Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.45.6.1911-1914.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

To determine if susceptibility testing of Streptococcus pneumoniae could detect those isolates that had one of the recognized mechanisms of fluoroquinolone resistance, 101 isolates were selected; the levofloxacin MIC for 28 of these isolates was ≥4 μg/ml. Only isolates with both parC andgyrA mutations or with no recognized resistance mechanisms were reliably identified by using these results. Isolates with only a parC mutation could not be detected reliably using any susceptibility testing method.

Decreased susceptibility ofStreptococcus pneumoniae to fluoroquinolones has been documented (3, 8) and in one study was associated with increased fluoroquinolone use (3). Fluoroquinolones inhibit bacterial growth by trapping gyrase or topoisomerase IV on DNA as ternary drug-enzyme-DNA complexes (4).

Decreased susceptibility to fluoroquinolones may develop as a result of changes in the fluoroquinolone targets by mutations in the genes which encode ParC in topoisomerase IV and GyrA in DNA gyrase and/or by diminished drug accumulation by efflux (7, 9, 10, 17, 19, 20). Mutations in gyrB have not to date been associated with decreased susceptibility to the fluoroquinolones inS. pneumoniae, and whether mutations in parEalter the susceptibility is still controversial (1, 16, 17). Mutations in parC and gyrA occur in the quinolone resistance-determining region (QRDR) of the genes. InS. pneumoniae, the target to which the fluoroquinolone has the greatest binding affinity (primary target) depends on the fluoroquinolone (7, 9, 10, 17, 19). For levofloxacin and ciprofloxacin, the primary target is ParC. For gatifloxacin and moxifloxacin, the primary target is GyrA (18). Mutations in the primary target that result in a reduction in the affinity of the fluoroquinolone are associated with an increase in the MIC. A subsequent mutation in the original secondary target will result in a further increase in the MIC (7, 9, 10, 17, 19, 20). Laboratory identification of isolates with decreased susceptibility to fluoroquinolones is paramount for the effective treatment of patients with pneumococcal disease. Of equal importance may be the ability to detect isolates that have a fluoroquinolone resistance mechanism, even if the isolate is still susceptible, since this organism may more readily become resistant during therapy when a subsequent mutation occurs in the original secondary target. In this study, we compared the activities of ciprofloxacin and levofloxacin by broth microdilution, disk diffusion, and E-test susceptibility testing procedures against clinical isolates of S. pneumoniae for which the fluoroquinolone MICs varied in order to determine if the results could be used to reliably distinguish an isolate with one or more fluoroquinolone resistance mechanisms from one with no resistance mechanisms.

S. pneumoniae clinical isolates were from the Canadian Bacterial Surveillance Network; their collection and identification have been detailed elsewhere (1, 3). The initial in vitro broth microdilution testing and subsequent disk diffusion testing of ciprofloxacin (using a 5-μg disk; Oxoid, Nepean, Ontario, Canada) and levofloxacin (using a 5-μg disk; Becton Dickinson and Co., Cockeysville, Md.) were done according to National Committee for Clinical Laboratory Standards (NCCLS) (3, 12, 13). NCCLS disk diffusion testing breakpoints for levofloxacin are as follows: susceptible, ≥17 mm; intermediate >13 and <17 mm; and resistant, ≤13 mm. MIC breakpoints are as follows: susceptible, ≤2 μg/ml; intermediate, 4 μg/ml; and resistant, ≥8 μg/ml. The antimicrobials were provided by their respective manufacturers. The E-test was performed according to the manufacturer's instructions. Following storage at −70°C, isolates were thawed and subcultured onto blood agar (Oxoid) twice before susceptibility testing was performed. A total of 101 clinical isolates were selected for analysis; these included 75 isolates for which the ciprofloxacin MIC was ≥4 μg/ml (MICs of 64 μg/ml for 6 isolates, 32 μg/ml for 4, 16 μg/ml for 12, 8 μg/ml for 12, and 4 μg/ml for 41), 14 for which the MIC was 2 μg/ml, 3 for which the MIC was 1 μg/ml, and 9 for which the MIC was <1 μg/ml.

Crude cell lysates were used as DNA templates for PCR. Briefly, a loopful of overnight growth on Columbia nutrient agar supplemented with 5% sheep blood was suspended in 100 μl of lysis buffer (100 mM NaCl, 10 mM Tris-HCl [pH 8.3], 1 mM EDTA, 1% Triton X-100) and boiled for 10 min; 10 μl of the supernatant was used as a template in a 50-μl reaction volume. QRDR regions of parC and gyrA of all strains were amplified by PCR. Primers were based on published sequences (14, 16). Amplification products were purified using either the QIAquick PCR purification kit (Qiagen Inc., Mississauga, Ontario, Canada) or the Concert Rapid PCR Purification (Life Technologies, Burlington, Ontario, Canada).

DNA sequencing was performed by ABI Prism Big Dye terminator cycle sequencing with the ABI 377 automated sequencer (PE Applied Biosystems, Mississauga, Ontario, Canada). Nucleotide and protein sequence comparisons were performed using the multiple alignment sequence function of Vector NTI Suite software (InforMax Inc., Bethesda, Md.). The GenBank accession numbers for wild-type sequences used for comparison purposes were Z67739 for parC andparE (15), AB010387 for gyrA, andZ67740 for gyrB (11).

Isolates were examined for active efflux by agar dilution on Mueller-Hinton agar containing 5% sheep blood in the presence of ciprofloxacin with or without 10 mg of the alkaloid reserpine (Sigma Chemical Co., St. Louis, Mo.) per ml (2). Strains for which the ciprofloxacin MIC decreased at least fourfold in the presence of reserpine were considered positive for active efflux.

Using two-by-two tables, a wide range of MICs or disk diffusion diameters were tested to find the threshold with the highest sensitivity and specificity for detecting resistance mechanisms. For positive and negative predictive values, the estimated prevalence of these resistance mechanisms in the 7,551 isolates from the Canadian Bacterial Surveillance Network was used (3).

There were 27 isolates with mutations in the QRDR of bothparC and gyrA, 3 of which were also positive for efflux. Fifty isolates had an isolated parC mutation, and none had an isolated gyrA mutation. Of those with aparC mutation but no gyrA mutation, 14 were also positive for efflux. Finally, there were 24 isolates with neither aparC nor a gyrA mutation, 9 of which were positive for efflux, leaving 16 with no identified resistance mechanisms.

Figure 1A graphs the broth microdilution MICs versus the disk diffusion diameters for levofloxacin, with the breakpoints for each shown. There were no major, or very major, errors. Figure 1B graphs the broth microdilution MICs versus the disk diffusion diameters for ciprofloxacin. Table 1summarizes the results for the three susceptibility testing methods. The NCCLS breakpoints for levofloxacin classified the 27 isolates with both parC and gyrA mutations as intermediate or resistant. There was only one isolate with aparC mutation but no gyrA mutation that was nonsusceptible (intermediate susceptibility). Interestingly, it did have a very active efflux mechanism (the ciprofloxacin MIC for this isolate decreased by 16-fold in the presence of reserpine). Other than for this isolate, efflux did not contribute to an increase in the levofloxacin MIC that resulted in a strain being classified as nonsusceptible.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Scattergram showing correlations among levofloxacin (A) and ciprofloxacin (B) MICs and zone diameters around 5-μg disks. Numbers are the datum points at each location (101 isolates tested).

View this table:
  • View inline
  • View popup
Table 1.

Isolates with and without gyrA and/orparC mutations and their susceptibility category classification according to NCCLS breakpoints for levofloxacin using three different testing methods

Table 2 summarizes the test characteristics of the three different susceptibility testing methods for detecting isolates with mutations in both parC andgyrA. MIC and disk diffusion values that favored a higher sensitivity were chosen. The prevalence used to determine the positive and negative predictive value is 0.4% (27 of 7,551 isolates). For detecting isolates with both gyrA and parCmutations, the levofloxacin E-test and disk diffusion tests were the most sensitive and specific. Using the levofloxacin E-test, a MIC of >2 μg/ml had a sensitivity of 100% and a specificity of 99%. The levofloxacin disk diffusion test had the same sensitivity and specificity using a disk diameter of less than 17 mm. These MIC and disk diffusion values are the same as the NCCLS breakpoints.

View this table:
  • View inline
  • View popup
Table 2.

Test characteristics of three susceptibility testing methods for detecting isolates with both parC andgyrA mutations

Table 3 considers only the levofloxacin-susceptible isolates (levofloxacin MIC of ≤2 μg/ml,n = 73) and summarizes the test characteristics of the three different susceptibility testing methods for detecting isolates with only a mutation in parC from among these isolates. No one MIC or disk diffusion value had a high sensitivity and specificity. For all testing methods, the negative predictive value was 100%. The prevalence used to calculate positive and negative predictive values was 1.0% (77 of 7,551 isolates). For detecting isolates with either aparC mutation or an active efflux mechanism among susceptible isolates, the test characteristics could be slightly improved. For example, in the best case, a disk with a diameter of <22 mm for levofloxacin had a sensitivity of 79% and a specificity of 93% (other data not shown).

View this table:
  • View inline
  • View popup
Table 3.

Test characteristics of three susceptibility testing methods for detecting isolates with parC mutations(n = 49) from among all 73 isolates susceptible to levofloxacin

S. pneumoniae isolates with mutations in the QRDR regions of both parC and gyrA genes are often not only resistant to levofloxacin but also nonsusceptible to moxifloxacin and gatifloxacin (3). We were able to reliably predict those isolates with both parC and gyrA mutations as well as those with no resistant mechanisms. However, it may be more important clinically and epidemiologically to be able to detect those isolates with first-step mutations. The likelihood of a wild-type isolate acquiring mutations in both of these genes simultaneously is on the order of 1 in 1012 to 1 in 1014(6). However, if an infecting organism has a mutation in one of the targets, the likelihood of a mutation occurring in the other target is on the order of 1 in 106 to 1 in 107 (6). In pneumococcal pneumonia, the bacterial burden is >1010, making the likelihood of a spontaneous mutation in the second target high (5). Unfortunately, no test had both a sensitivity and a specificity adequate for reliably identifying susceptible isolates with single mutations. Future studies should address this deficiency.

The large number of clinical isolates in our study enhances the validity of our findings with recognized fluoroquinolone-resistant mechanisms. A weakness of the study is that all the mechanisms of resistance were selected for during a time when the only fluoroquinolones in clinical use had preferential affinity for ParC over GyrA (i.e., norfloxacin, ofloxacin, ciprofloxacin, and levofloxacin). To further validate our findings, it may be necessary to assess clinical pneumococcal isolates with fluoroquinolone resistance mechanisms that have been selected for both by agents that have preferential ParC affinity and the newer agents with preferential GyrA affinity (i.e., moxifloxacin and gatifloxacin). Finally, these results are based primarily on a selected collection of isolates for most of which the ciprofloxacin MICs were ≥4 μg/ml, and the prevalence values could only be estimated from this small collection.

ACKNOWLEDGMENTS

This study was supported in part by a grant from the Canadian Bacterial Diseases Network.

FOOTNOTES

    • Received 23 October 2000.
    • Returned for modification 23 February 2001.
    • Accepted 15 March 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Bast D. J.,
    2. Low D. E.,
    3. Duncan C. L.,
    4. Kilburn L.,
    5. Mandell L. A.,
    6. Davidson R. J.,
    7. de Azavedo J. C.
    Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44 2000 3049 3054
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Brenwald N. P.,
    2. Gill M. J.,
    3. Wise R.
    Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42 1998 2032 2035
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Chen D.,
    2. McGeer A.,
    3. de Azavedo J. C.,
    4. Low D. E.,
    5. The Canadian Bacterial Surveillance Network
    Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341 1999 233 239
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Fournier B.,
    2. Zhao X.,
    3. Lu T.,
    4. Drlica K.,
    5. Hooper D. C.
    Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob. Agents Chemother. 44 2000 2160 2165
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Frisch A. W.,
    2. Tripp J. W.,
    3. Barrett C. D.,
    4. Pidgeon B. E.
    The specific polysaccharide content of pneumonic lungs. J. Exp. Med. 76 1942 505 510
    OpenUrlAbstract
  6. 6.↵
    1. Fukuda H.,
    2. Hiramatsu K.
    Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43 1999 410 412
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gootz T. D.,
    2. Zaniewski R.,
    3. Haskell S.,
    4. Schmieder B.,
    5. Tankovic J.,
    6. Girard D.,
    7. Courvalin P.,
    8. Polzer R. J.
    Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40 1996 2691 2697
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ho P. L.,
    2. Que T. L.,
    3. Tsang D. N.,
    4. Ng T. K.,
    5. Chow K. H.,
    6. Seto W. H.
    Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43 1999 1310 1313
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Janoir C.,
    2. Zeller V.,
    3. Kitzis M. D.,
    4. Moreau N. J.,
    5. Gutmann L.
    High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40 1996 2760 2764
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Jorgensen J. H.,
    2. Weigel L. M.,
    3. Ferraro M. J.,
    4. Swenson J. M.,
    5. Tenover F. C.
    Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA,parC, and parE loci. Antimicrob. Agents Chemother. 43 1999 329 334
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Munoz R.,
    2. Bustamante M.,
    3. De La Campa A. G.
    Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J. Bacteriol. 177 1995 4166 4170
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7–A5. NCCLS document M100–S10/M7. 2000 National Committee for Clinical Laboratory Standards Wayne, Pa
  13. 13.↵
    National Committee for Clinical Laboratory Standards Performance standards for antimicrobial disk susceptibility tests. Approved standard. NCCLS document M2–A7. 2000 National Committee for Clinical Laboratory Standards Wayne, Pa
  14. 14.↵
    1. Pan X. S.,
    2. Ambler J.,
    3. Mehtar S.,
    4. Fisher L. M.
    Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40 1996 2321 2326
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Pan X. S.,
    2. Fisher L. M.
    Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178 1996 4060 4069
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Perichon B.,
    2. Tankovic J.,
    3. Courvalin P.
    Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41 1997 1166 1167
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Pestova E.,
    2. Beyer R.,
    3. Cianciotto N. P.,
    4. Noskin G. A.,
    5. Peterson L. R.
    Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob. Agents Chemother. 43 1999 2000 2004
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Pestova E.,
    2. Millichap J. J.,
    3. Noskin G. A.,
    4. Peterson L. R.
    Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45 2000 583 590
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Tankovic J.,
    2. Perichon B.,
    3. Duval J.,
    4. Courvalin P.
    Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40 1996 2505 2510
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Zhanel G. G.,
    2. Walkty A.,
    3. Vercaigne L.,
    4. Karlowsky J. A.,
    5. Embil J.,
    6. Gin A. S.,
    7. Hoban D. J.
    The new fluoroquinolones: a critical review. Can. J. Infect. Dis. 10 1999 207 238
    OpenUrl
PreviousNext
Back to top
Download PDF
Citation Tools
Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae
David C. Richardson, Darrin Bast, Allison McGeer, Donald E. Low
Antimicrobial Agents and Chemotherapy Jun 2001, 45 (6) 1911-1914; DOI: 10.1128/AAC.45.6.1911-1914.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae
David C. Richardson, Darrin Bast, Allison McGeer, Donald E. Low
Antimicrobial Agents and Chemotherapy Jun 2001, 45 (6) 1911-1914; DOI: 10.1128/AAC.45.6.1911-1914.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

anti-infective agents
Streptococcus pneumoniae

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596